Published September 30, 2026 | Version v1
Report Open

ENCLAI Evidence Digest — September 2026

Authors/Creators

  • 1. ENCLAI (Enclai LLC)

Description

Monthly ENCLAI Evidence Digest, issue 2026-09. Four features, one per therapeutic area, chosen by patient impact from the study and FDA-approval articles ENCLAI published in September 2026:

  • Oncology: Retlirafusp alfa plus chemotherapy beats chemo alone in HER2-negative gastric cancer
  • Respiratory: Inhaled treprostinil slows lung function loss in IPF
  • Neurology: Isembyld approved as an add-on treatment for spinal muscular atrophy
  • Vaccines: Silevimig matches human rabies immunoglobulin in phase III trial

Every number is checked against its exact source sentence; charts are drawn by code from verified values. ENCLAI ID: ENCLAI-2026-0000476-5 (https://enclai.net/id/ENCLAI-2026-0000476-5).

Files

enclai_evidence_digest_2026-09.pdf

Files (8.9 MB)

Name Size Download all
md5:772c2a96aae9bb2ec13ebd5c7606f920
8.9 MB Preview Download

Additional details

Related works

Is identical to
Report: https://enclai.net/digest/2026-09 (URL)